 |
26 Diseases |  |
6 Trials |
|
6 Trials |  |
4342 News |  |
| «12...2122232425262728293031...5051» |
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
The free fatty acid EPA in Epanova is much more bioavailable than the ethyl ester in EPA. So if you look at the trials for hypertriglyceridemia the just over 2g of EPA fatty acid actually achieves as high levels of EPA as 4 gram of ethyl ester in Vascepa (Twitter) - Oct 23, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Head-to-Head: 1/ #Vascepa Has there been a head to head with Lozaza? The cost has to be a consideration. I have done very well with Lovaza. (Twitter) - Oct 23, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Except the trials prove it has nothing to do with TG level. Vascepa lowers cardiovascular risk 30% and Lovaza does absolutely nothing. So a better question is whether you’re patient is wasting their $10 copay on lovaza for no benefit at all (Twitter) - Oct 23, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Clinical: One note - earlier studies of EPA levels for Epanova showed even higher EPA levels than Vascepa for equal dose since it has higher bioavailability. So the mention of EPA dose is prob not the case which is even more interesting. (Twitter) - Oct 23, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Even more than that, blood EPA levels are even higher with Epanova than Vascepa due to increase bioavailability. So it’s essentially equal dose of EPA. (Twitter) - Oct 23, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
The evidence is for Vascepa not Lovaza. It is the EPA effect. (Twitter) - Oct 23, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
3/ #Vascepa I think most MD's don't know that 5,000 mg Lovaza may work in getting high TG down. @nationallipid @DaveDixonPharmD @mdavidsonmd (Twitter) - Oct 23, 2020
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Adverse events: 2/ #Vascepa The new drugs are great but triple generic Rx must be attempted first because of cost. Low dose generic drugs in combination w few side effects work as well a PCSK9 drug to get LDLPp very low https://t.co/Snqg5l18ax (Twitter) - Oct 23, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
1/ #Vascepa @ErinMichos advising brand name EPA? Indication over cheaper Lovaza? Larger fluffier LDLp was never a problem in my practice @Drlipid I appreciated the academic approach but cost must be taken into consideration. My 3 generic drugs are probably cheaper than Vascepta (Twitter) - Oct 23, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT https://t.co/UY3fB5YqXi #cardiology #cardiometabolic #cardiotwitter @benpeterson71 @gabrielsteg @CMichaelGibson @duanepinto @mmillermd1 @CBallantyneMD @BudoffMd @jctardif_mhi @ToddNeale #TCT2020 (Twitter) - Oct 22, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] LS.07 - VASCEPA® (icosapent ethyl): Elevating the Standard of Care (Live - Learning Studio) - Oct 22, 2020 - Abstract #AHA2020AHA_5662;
In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care. Sponsored by: Amarin Pharma, Inc.
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: If your patient had a PCI - look at their Trig, and if >135 mg/dl - treat with icosapent ethyl. Big benefits! Presented at TCT by Ben Peterson with @DLBHATTMD https://t.co/zi98Ev3ZGP (Twitter) - Oct 22, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Retrospective data, Journal: Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. (Pubmed Central) - Oct 22, 2020
In the analysis excluding REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), marine omega-3 supplementation was associated with significantly lower risk of myocardial infarction (rate ratio [RR] [95% CI]: 0.92 [0.86, 0.99]; P=0.020), CHD death (RR [95% CI]: 0.92 [0.86, 0.98]; P=0.014), total CHD (RR [95% CI]: 0.95 [0.91, 0.99]; P=0.008), CVD death (RR [95% CI]: 0.93 [0.88, 0.99]; P=0.013), and total CVD (RR [95% CI]: 0.97 [0.94, 0.99]; P=0.015)...Conclusions Marine omega-3 supplementation lowers risk for myocardial infarction, CHD death, total CHD, CVD death, and total CVD, even after exclusion of REDUCE-IT. Risk reductions appeared to be linearly related to marine omega-3 dose.
- || Praluent (alirocumab) / Sanofi, Regeneron, icosapent ethyl / Generic mfg., Repatha (evolocumab) / Amgen, Astellas
Review, Journal: Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. (Pubmed Central) - Oct 22, 2020
Similar results were observed with alirocumab use in a post hoc analysis of the ODYSSEY OUTCOMES trial where a genome-wide polygenic risk score comprising 6.5 million DNA variants was used. These studies presented at 2019 AHA Scientific Sessions will help guide our approach to preventing CVD.
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Review, Journal: Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. (Pubmed Central) - Oct 21, 2020
In addition, we review the BPLTTC analysis on blood pressure treatment across blood pressure levels and CVD status and discuss findings from the BRACE CORONA study that examined continuing versus suspending angiotensin-converting enzyme inhibitor or angiotensin receptor blockers in patients on these antihypertensive medications who were hospitalized with COVID-19 infection. The studies presented at the 2020 digital ESC Congress highlight the continuing advancements in the field of CVD prevention.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical, Journal: Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. (Pubmed Central) - Oct 20, 2020
The studies presented at the 2020 digital ESC Congress highlight the continuing advancements in the field of CVD prevention. No abstract available
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Journal: Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. (Pubmed Central) - Oct 20, 2020
REDUCE-IT demonstrated that high-dose EPA (4 g/day icosapent-ethyl) reduced a composite of clinical events by 25% in statin-treated patients with established CVD or diabetes and other cardiovascular risk factors...Here, we review these multifactorial mechanisms of ω3-PUFAs in view of recent clinical findings. These findings indicate physico-chemical and biological diversity among ω3-PUFAs that influence tissue distributions as well as disparate effects on membrane organization, rates of lipid oxidation, as well as various receptor-mediated signal transduction pathways and effects on gene expression.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical, Journal: Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. (Pubmed Central) - Oct 20, 2020
Over a median duration of 4.9 years, the relative risk for the primary endpoint (composite of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina) was reduced by 25% (absolute risk 17.2% vs. 22.0%; P < 0.0001; number needed to treat 21). High-dose icosapent ethyl intervention therefore confers substantial cardiovascular benefit in high-risk patients with moderate hypertriglyceridaemia on statin therapy.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical, Journal: Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. (Pubmed Central) - Oct 20, 2020
Interest in mineral oil was piqued by suggestions that a portion of the substantially positive results of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) might be attributable to the theoretical negative effects of mineral oil rather than being due to the clinical benefits of icosapent ethyl...These results were then considered alongside publicly available data from REDUCE-IT. Based on available evidence, mineral oil does not appear to impact medication absorption or efficacy, or related clinical outcomes, and, therefore, does not meaningfully affect study conclusions when used as a placebo at the quantities used in clinical trials.
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Journal: Beyond cardiovascular medicine: potential future uses of icosapent ethyl. (Pubmed Central) - Oct 20, 2020
These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer's disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Vascepa, especially it will be generic in the US. $AMRN (Twitter) - Oct 19, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] TCT ID 3: Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention – Insights From REDUCE-IT PCI (Main Arena) - Oct 19, 2020 - Abstract #TCT2020TCT_424;
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Review, Journal: Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease? (Pubmed Central) - Oct 16, 2020
Clinical trials supporting the addition of ezetimibe, PCSK9 inhibitors, or both to evidence-based statins provide the basis for the updated recommendations for the preventive care of these patients. The publication in late 2018 of a randomized controlled trial supporting the net ASCVD risk reduction benefit of adding icosapent ethyl to statins in selected hypertriglyceridemic patients with clinical ASCVD and/or type 2 diabetes with multiple additional risk markers provides the rationale for incorporation of icosapent ethyl therapy into future ASCVD preventive care regimens.
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: @DLBHATTMD REDUCE it PCI ! As @agershlick says unbelievable! More excellent results with small numbers nnt, #TCTconnect Icosapent ethyl PCI patients data (Twitter) - Oct 15, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Read the valuable insights from Dr. Christopher Cannon about the REDUCE-IT trial and underuse of icosapent ethyl: Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated https://t.co/im03If6DnV @cpcannon #cardiotwitter #cardiology (Twitter) - Oct 12, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Benefits of Icosapent Ethyl Across a Range of Baseline Renal Function in Patients with Established Cardiovascular Disease or Diabetes: Results of REDUCE-IT RENAL (Simulive) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3535;
The publication in late 2018 of a randomized controlled trial supporting the net ASCVD risk reduction benefit of adding icosapent ethyl to statins in selected hypertriglyceridemic patients with clinical ASCVD and/or type 2 diabetes with multiple additional risk markers provides the rationale for incorporation of icosapent ethyl therapy into future ASCVD preventive care regimens. In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories.
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Icosapent Ethyl (OM3FA) and its potential benefits in Depression,Alzhimers Dementia , Colorectal cancer and Infections published by @DLBHATTMD and #DrPeterToth in @escardio @ESC_Journals #CardiovascularPrevention https://t.co/anyhhfsBVk (Twitter) - Oct 11, 2020
- | icosapent ethyl / Generic mfg.
Journal: A Response to: Letter to the Editor Regarding "Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review". (Pubmed Central) - Oct 10, 2020
In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. No abstract available
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
⚠️ Beyond cardiovascular medicine: potential future uses of icosapent ethyl by @DLBHATTMD @ESC_Journals @escardio @secardiologia https://t.co/0TmtOkGacp (Twitter) - Oct 10, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG (OnDemand) - Oct 10, 2020 - Abstract #AHA2020AHA_5239;
No abstract available In statin-treated patients with a history of prior CABG, the addition of icosapent ethyl significantly reduced ischemic events, with both large relative and absolute risk reductions.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Are the Results of Clinical Trials Relevant in the Real World? The Applicability of Reduce-It to the Fast-MI Registry (OnDemand) - Oct 10, 2020 - Abstract #AHA2020AHA_5124;
The cardiovascular residual risk related to elevated TG in the applicable patient population in the FAST-MI registry was similar to the risk in REDUCE-IT. If the results of REDUCE-IT are applied to patients hospitalized for a myocardial infarction in France, on top of statins, 12.5% of these patients could benefit from a strategy of high dose omega-3 icosapent ethyl.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Andrew: Twitter is an open forum, and indeed we live in a free country but you are not qualified to seriously critique the names you mention. Make your own name with original and independent thinking and then report back $AMRN Icosapent Ethyl (Twitter) - Oct 9, 2020
- || Lypdiso (omega-3 pentaenoic acid) / Matinas
Enrollment closed: ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - Oct 9, 2020
P2, N=100, Active, not recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
If the results of REDUCE-IT are applied to patients hospitalized for a myocardial infarction in France, on top of statins, 12.5% of these patients could benefit from a strategy of high dose omega-3 icosapent ethyl. Recruiting --> Active, not recruiting
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Thank you for the outstanding analysis, @DLBHATTMD. Looking forward to the next chapter in the history of icosapent ethyl in CV medicine and beyond! (Twitter) - Oct 7, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside https://t.co/gmoPkLE49U #cardiology #cardiotwitter @ESC_Journals @escardio (Twitter) - Oct 7, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap https://t.co/Xt869EDcnK #cardiology #cardiotwitter @ESC_Journals @escardio (Twitter) - Oct 7, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Beyond cardiovascular medicine: potential future uses of icosapent ethyl https://t.co/qMywWLYVph #cardiology #cardiotwitter #COVID19 (Twitter) - Oct 7, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: But Dr Bhatt AMARIN lost . How was the Mori Study not fully refuted during the initial case? People lost millions believing in you and JT. Where were the institutions that hailed VASCEPA when that was happening. #Sad #Abuseofpower by the Judiciary (Twitter) - Oct 7, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: If you want a quick recap of icosapent ethyl through REDUCE-IT and beyond, here it is! Now in this @ESC_Journals supplement. Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside https://t.co/bijd7G22Vx #cardiotwitter #cardiology @escardio (Twitter) - Oct 6, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: @PeterlinMD and @DLBHATTMD I read your practice update but I think you might want to read this thread- I still find it hard to believe the placebo harm did more harm than the active arm did benefit and STILL #icosapentethyl remains a 'magical wonderful drug' - change your mind? (Twitter) - Oct 5, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: When should we expect to know the results of #vascepa testing on covid-19 patients? (Twitter) - Oct 5, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
@DLBHATTMD Knowing what you know about @POTUS's health & condition, would you recommend that he take Vascepa? $AMRN (Twitter) - Oct 5, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
"The purpose of this review is to outline the effects of icosapent ethyl (IPE), an ultra-purified eicosapentaenoic acid (EPA) on ASCVD risk assessment." @NajdatBazarbas1 https://t.co/wBFrZKhfWp (Twitter) - Oct 4, 2020
- ezetimibe / Generic mfg., inclisiran (ALN-PCSsc) / Alnylam, Novartis, Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] RESIDUAL CHOLESTEROL RISK - A MOVING TARGET (Inxpo Platform, Simulive + Live Q&A) - Oct 4, 2020 - Abstract #CCCCanada2020CCC_Canada_197;
c. Inclisiran-Novel approach to ultra-low LDL?
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] SIGNIFICANT CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL FROM REDUCE-IT (Inxpo Platform, Simulive + Text Q&A) - Oct 4, 2020 - Abstract #CCCCanada2020CCC_Canada_92;
On-treatment EPA strongly correlated with event reductions, providing mechanistic underpinnings for the sizable risk reductions. Serious adverse events that occurred at higher rates with IPE, were low overall, and patients experienced similar substantial cardiovascular benefit.
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap, Parmodia (pemafibrate) / Kowa
Review of icosapent ethyl (Vascepa) by @CBallantyneMD highlighting REDUCE-IT and guidelines recommending add't of Vascepa, as well as future directions for TG-lowering in CV risk reduction. Excited for the potential of pemafibrate. #EASCongress2020 (Twitter) - Oct 4, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Not all Fish oils are the same . EPA-only prescription product ; 100% icosapent ethyl #EASCongress2020 @EASCongress @Steph_Achenbach @pabeda1 @SABOURETCardio @BethFratesMD @GaitaDan @DBelardoMD @ESC_Journals @DavidLBrownMD @DLBHATTMD @VLSorrellImages @atvbahajournals (Twitter) - Oct 4, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Journal: Editorial commentary: Icosapent ethyl in the treatment and prevention of cardiovascular disease. (Pubmed Central) - Oct 4, 2020
Serious adverse events that occurred at higher rates with IPE, were low overall, and patients experienced similar substantial cardiovascular benefit. No abstract available
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
This seems to me to be a misleading title. This is the value of Icosapent ethyl (Vascepa) , not the value of Omega 3 FA. (Twitter) - Oct 4, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada. () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1369;
IPE represents an important new treatment for the reduction of ischemic cardiovascular events. Based on the clinical trial evidence, this CUA suggests that IPE is a cost-effective strategy in Canada based on the conventionally quoted thresholds of $50,000 per QALY gained.